“Could treatment do more than ease today’s symptoms and also slow future worsening?” That is the hope behind many Parkinson’s studies. This issue covers two medicines designed to support functions inside nerve cells. One announcement concerns scores followed for a year; the other concerns early safety and whether a medicine reaches the brain. These are different achievements, not two proven treatments for slowing Parkinson’s.
Oral rexaceract: movement scores remained broadly stable over 12 months
🔍 What the study found
On October 1, Gain Therapeutics announced results from the extension of its Phase 1bAn early trial stage focused mainly on safety and how well treatment is tolerated. Exploratory symptom changes do not establish effectiveness.Learn more study of rexaceract, previously called GT-02287. In 12 evaluable people who completed 12 months of daily oral treatment, movement and daily-function scores remained broadly stable compared with study entry, according to the company.
Rexaceract is designed to support GCaseAn enzyme that breaks down certain fats inside cells. Supporting its function is a research goal, not an established clinical benefit.Learn more, an enzyme involved in breaking down certain fats. Cells have systems that remove and recycle unwanted material. Problems with these functions are a focus of Parkinson’s research, so this approach differs from simply supporting dopamine signalling. The proposed mechanism does not itself prove that human nerve cells are protected or disease progression is stopped.
The announcement assessed MDS-UPDRSA scale used to assess Parkinson's symptoms and daily difficulties. Part II covers daily activities and Part III is a clinician's movement examination.Learn more Parts II and III: difficulties with activities such as eating, dressing and walking, and a clinician’s examination of movement. Stable scores mean that marked worsening was not observed on these measures, not that every symptom disappeared.
The extension had no placebo comparison, and participants and researchers knew which treatment was given. With so few people, natural fluctuations and other influences cannot be separated reliably from drug effects. This is a signal worth testing in a larger comparison, not proof of disease modification. The developer plans to begin Phase 2A trial stage exploring effectiveness, safety and dosing in people with the condition. A planned trial is not approval or availability.Learn more in the first quarter of 2027. That is a development plan, not a date for prescription availability. These findings come from a developer announcement, not independent confirmation of clinical effectiveness.
✅ If you live with Parkinson’s
The hopeful development is longer human observation of a medicine aiming beyond symptom relief. It does not mean rexaceract is available on prescription or better than current medicines. Treatments such as levodopa remain important for managing symptoms. Waiting for an investigational medicine is not a reason to delay or reduce current care.
When a headline says a medicine might slow progression, ask: Was there a comparison group? How long were people followed? Were everyday activities assessed? A year of follow-up is useful, but the lack of a comparison group must be read alongside the result.
🙋 If you are a care partner
Describe changes in concrete activities: time needed to dress independently, difficulty eating or walking, and whether problems cluster around medicine times. This can help a clinician understand everyday function rather than relying on a single impression such as “more tremor.”
Family records cannot determine disease progression by themselves. Use them to support a clinical assessment, not diagnose worsening at home. When discussing research, distinguish a hopeful early signal from a treatment with demonstrated benefit; that helps keep expectations grounded.
Weekly TT-P34 injections: first human trial reports safety and brain exposure
🔍 What the study found
On September 10, Danish developer Teitur Trophics announced Phase 1 results for TT-P34. The randomized, double-blind, placebo-controlled trial involved 55 healthy volunteers and 12 people with early Parkinson’s. The 12-person cohort includes the whole Parkinson’s group; it does not mean all 12 received active medicine.
TT-P34 is designed to support energy production and cellular waste processing. MitochondriaStructures that produce energy cells need. Benefits of medicines targeting them must be tested in people.Learn more produce energy, while lysosomesStructures that break down and recycle unwanted material inside cells. Targeting them is not proof of treatment effectiveness.Learn more break down unwanted material. Nerve cells need both functions, which is why this dual approach is being investigated. Benefits for people remain to be tested.
The company reported encouraging safety and tolerabilityHow well people can tolerate treatment, including adverse effects. This is different from whether treatment works.Learn more with weekly injections under the skin, without dose-limiting findings at the tested doses. The Parkinson’s cohort also evaluated use alongside levodopa. Drug-exposure analyses indicated that TT-P34 reached the brain and central nervous system.
Why does reaching the brain matter? A medicine targeting nerve cells must get to the relevant site to have its intended action. Crossing the blood-brain barrierA protective system limiting movement of substances from blood into brain tissue. Crossing it does not establish symptom improvement.Learn more is therefore an important development step. Brain exposure alone does not show less tremor or better walking.
This was primarily an early safety and drug-behaviour study, not an effectiveness trial. Only 12 people were in the Parkinson’s cohort, and the announcement described biomarker observations over 50 days. A small, short trial cannot settle long-term safety. The company plans Phase 2 in 2027 to explore benefit and possible effects on progression. Progress through these early checks is meaningful, but the desired treatment effect is still unproven.
✅ If you live with Parkinson’s
The hopeful step is that a nerve-cell protection approach has gained human data supporting further testing. Weekly dosing remains an investigational schedule, not evidence that one injection can replace daily Parkinson’s medicines.
Phase 1 mainly checks safety and related properties; Phase 2 explores effectiveness and dosing further. TT-P34 is still investigational. Do not stop existing treatment or buy similarly named products on the basis of this announcement.
🙋 If you are a care partner
“One injection a week” may suggest less treatment burden. Explain it as a candidate completing early safety testing, not a newly available replacement for current care.
If considering a trial, discuss eligibility, visits, tests, adverse-effect support and whether existing medicines continue with the care team. This announcement does not establish local trial recruitment or prescription availability. Watch for larger studies measuring improvements that matter in daily life.
What you can do now
Rexaceract has reported stable scores in a small uncontrolled year-long observation; TT-P34 has reported early safety and brain exposure. Both support further research, but neither establishes slower progression. Continue current care, describe daily changes to your clinician, and distinguish observed findings from hoped-for benefits when reading new research.
ParkinON explains recent developer announcements and study information in plain language. This is not medical diagnosis or treatment advice and does not establish approval or availability in your country.